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based on the same clinical studies and corresponded to improvement in respira-
tory symptoms (as measured by the CFQ-R). In one case, the improvement in res-
piratory symptoms was considered as primary endpoint (aztreonam lysine – one 
study). ConClusions: There are few PRO labeling claims in products approved for 
CF in Europe and the United States. Discrepancies exist in the CF guidance issued by 
the FDA and the EMA, where EMA is more favorable to PRO endpoints.
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objeCtives: Chronic low back pain is a persistent disabling condition that impairs 
the individual’s functional status and poses as an economic burden to the society. 
The objectives of this study were to examine the pain-related disability, self-effi-
cacy and coping strategies of adult patients with chronic low back pain and their 
relationships, the differences in pain-related disability, self-efficacy and coping 
strategies used among socio-demographic and clinical characteristic subgroups, 
and to identify the predictors of pain-related disability. Methods: A descriptive, 
correlational questionnaire survey design was used. A convenience sample of 65 
patients aged 21 years or above with a diagnosis of chronic low back pain was 
recruited from a public hospital in Singapore from September 2012 to January 2013. 
Roland-Morris Disability Questionnaire, Chronic Low Back Pain Self-Efficacy Scale, 
and Coping Strategies Questionnaire-24 were used to collect data. Descriptive statis-
tics, independent sample t-test, analysis of variance, and Peanson Product-moment 
Correlation Coefficent were used to analyse the data. Results: The participants 
had moderate levels of pain-related disability and self-efficacy, and used both active 
and passive coping strategies. Significant differences in pain-related disability, self-
efficacy and coping strategies used were found among subgroups of various socio-
demographics. Significant differences in pain-related disability were found within 
one subgroup of clinical variable. Pain-related disability had a significant negative 
relationship with self-efficacy and positive relationship with passive coping, while 
self-efficacy had a significant positive relationship with active coping and a nega-
tive relationship with passive coping. Self-efficacy, ethnicity and monthly income 
were predictors of pain-related disability. ConClusions: Our findings indicate 
the need to enhance patients’ self-efficacy and reduce the use of passive coping 
strategies in order to decrease pain-related disability. Future intervention studies 
improving patients’ self-efficacy and coping are needed to improve patients’ well-
being and quality of life.
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objeCtives: Patient-reported measures of Vaso Occlusive Crisis (VOC) outcomes 
reported in literature were identified and quality of evidence for each type of meas-
ure was assessed. Methods: PubMed, COCHRANE and CINAHL databases (1966 
through August 2012) and reference lists of identified articles were searched for any 
patient-reported measures employed to assess VOC outcomes. Identified measures 
were categorized as: measures assessing pain, and measures assessing quality of 
life (QoL) due to VOC. Studies were assessed for quality of evidence based on risk 
of bias (coded ‘1’ for randomized controlled study without any serious limitations, 
else ‘0’), consistency (coded ‘1’ for demonstrated clinical and methodological homo-
geneity, else ‘0’), directness (coded ‘1’ for use of non-surrogate endpoint, else ‘0’) 
and precision (coded ‘1’ if total number of cases across all studies of measure was 
greater than 400, else ‘0’). Overall quality of evidence was calculated by summation 
of each domain score, where ‘4’ meant ‘high,’ ‘3,’ ‘moderate,’ ‘2,’ ‘low’ and scores 
less than or equal to ‘1’ denoted ‘very low’ quality of evidence. Results: A total of 
1,620 potentially relevant studies were identified and reviewed. Of those, 63 stud-
ies passed inclusion criteria and were retained for analyses. Twenty-three unique 
patient-reported measures of VOC outcomes were identified and categorized. Fifty-
seven studies employed pain based measures and 12 studies employed QoL based 
measures. While, overall mean quality of evidence score was 2.17, mean quality of 
evidence score for pain based measures was 2.35 and for QoL based measures was 
1.42. The most commonly employed pain based measures were Visual Analog Scales 
(VAS), (28 studies), whereas, the most commonly employed QoL based measure was 
school/work attendance, (4 studies). ConClusions: A variety of patient-reported 
measures of VOC outcomes were identified and categorized. VAS, and face based 
scales had higher quality of evidence compared to measure of school/work attend-
ance.
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objeCtives: 1) To identify products indicated for the treatment of rare diseases 
approved through the centralized procedure in Europe, and (2) To list the products 
which obtained a PRO labeling claim. Methods: The search was performed on 
the European Medicines Agency (EMA) website (11/12/2013). The European public 
assessment reports (EPARs) were browsed by type (i.e., orphan medicines). Products 
refused were excluded. Then, the PROLabels database was searched for each product 
retrieved to identify any PRO claim in the corresponding label. Results: A total of 
69 orphan medicines were identified on the EMA website, representing 11 different 
objeCtives: Despite the clearly evident better clinical outcomes with prophy-
laxis compared to on-demand therapy, on average only 55% of patients diagnosed 
with severe hemophilia receive prophylactic factor replacement therapy in the US. 
Prophylaxis generally drops with age, partly due to patients becoming more inde-
pendent and less compliant as they reach adulthood and partly due to reduced 
perceived benefit. High treatment costs of prophylaxis therapy also remains a 
barrier. Further, the development of long-acting factor products offering a mod-
est improvement in convenience is likely to drive-up treatment costs. This study 
aims to understand hemophilia patient preferences and their willingness-to-pay 
for hemophilia therapies (on-demand, standard prophylaxis, longer-acting prophy-
laxis). Methods: U.S. adult patients and caregivers of children with hemophilia (n 
= 79) completed a discrete-choice survey that presented a series of trade-off ques-
tions, each including a pair of hypothetical treatment profiles, that had an assigned 
cost for attaining improvement in health states. The relative importance of treat-
ment attributes such as out-of-pocket treatment costs, dose adjustment, treatment 
related complications and clinical efficacy & dosing regimen was analyzed using 
mixed logit models. Based on the attribute estimates, patients’ WTP was deter-
mined. Results: Out-of-pocket treatment costs (P < .001), treatment complications 
(P < .001) and clinical efficacy & dosing regimen (P < .001) were perceived to be the 
most important treatment attributes. Patients were willing to pay on average $150 
per/month for improvement in each of the prophylaxis dosing regimens (i.e. 3 times 
weekly vs 2 times weekly vs. 1 time weekly vs. 1 time in two weeks). ConClusions: 
The results suggest that patients are willing to pay more for improvements in treat-
ment related complications, clinical efficacy & dosing regimen. These estimates of 
patients’ willingness-to-pay can be used to provide guidelines for resource alloca-
tion. Literature also suggests that patient preferences are likely to directly translate 
into increased treatment adherence, leading to greater treatment effectiveness.
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objeCtives: Phenylketonuria (PKU) is the most common in-born error of metabo-
lism and is associated with neuropsychiatric sequelae. Interviews among adults 
and parents of children with PKU have established that inattentiveness is an 
important psychiatric symptom. Although the Adult ADHD Self-Rating Scale (ASRS; 
self-report) and ADHD Rating Scale (ADHD RS-IV; parent-report) instruments have 
been validated for measuring symptoms of inattentiveness in persons with ADHD, 
their psychometric value for measuring PKU-related inattentiveness has not been 
established. This study investigated the psychometric properties of the ASRS and 
ADHD RS-IV inattentiveness subscales in a PKU population ≥ 8 years old. Methods: 
A post-hoc analysis was conducted in participants ≥ 8 years of age in a Phase 3b 
double blind, placebo-controlled clinical trial in PKU over a 13-week period. The 
ASRS/ADHD RS-IV reliability, construct validity, and responsiveness were meas-
ured using clinician- and adult-/parent-reported outcomes collected in this clini-
cal trial. Results: Data analysis revealed strong internal consistency reliability 
for both measures (α ≥ 0.87). In addition, the test-retest analyses resulted in ICCs 
≥ 0.87, indicating outstanding agreement between the Baseline and Week 4 (re-test 
visit) measures for both the adult- and parent-rated inattentiveness subscales. Both 
inattentiveness measures demonstrated an ability to discriminate between known 
groups (p< 0.0001) defined by the Clinical Global Impression-Severity (CGI-S) scale. 
Correlations between the ASRS/ADHD RS-IV with the CGI-S and age-appropriate 
Behavior Rating Inventory of Executive Function (BRIEF) Working Memory subscale 
were consistently moderate-to-strong (r ≥ 0.56). Similarly, results of the change score 
correlations were moderate (r ≥ 0.43) for both measures when compared to changes 
over time in the BRIEF Working Memory subscale. ConClusions: These findings 
of reliability, validity, and responsiveness of both the ASRS and the ADHD RS-IV 
inattentiveness sub-scales, in addition to content validation results, further support 
their use for the assessment of inattentive symptoms among persons with PKU ≥ 8 
years old in clinical trials.
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objeCtives: The objective of this research was to review the role of patient-reported 
outcomes (PROs) in drug approval and labeling of products authorized for the treat-
ment of cystic fibrosis (CF) in Europe and in the United States. Methods: This 
research was conducted through a systematic manual review of CF specific regula-
tory guidelines and product labelings (US and EU). The PROLabels database was used 
for the label review. FDA medical reviews and EMA assessment reports were also 
used to review the clinical studies performed for regulatory approval. Results: 
In its guideline specific to CF, the EMA recommends the use of the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) and labels it as a quality-of-life endpoint. The CFQ-R 
is a disease-specific instrument designed to measure impact on overall health, 
daily life, perceived well-being and symptoms. There is no specific FDA guidance 
on CF: the corresponding FDA guidance only covers exocrine pancreatic insuffi-
ciency drug products and recommends steatorrhea as the main endpoint. A total of 
seven different products (seven brand names, six INN) indicated for the treatment 
of cystic fibrosis were identified: five were approved by the EMA, and five by the 
FDA. Three products were common to both agencies: aztreonam lysine, ivacaftor 
and tobramycin. Two products were identified with a PRO claim in Europe and in 
the United States, i.e., aztreonam lysine and ivacaftor. In both cases, the claim was 
